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Summary 
The major histocompatibility complex class I-restricted cytotoxic T lymphocyte (CTL) response 
is important in the clearance of viral infections in humans. After influenza A infection, a peptide 
from the matrix protein, M58-66, is presented in the context of the MHC allele HLA-A0201 
and the resulting CTL response is detectable  in most HLA-A0201 subjects.  An initial study 
suggested that M58-66-specific  CTL clones show conserved T  cell receptor (TCR) c~ and 
gene segments. We have addressed the significance of this observation by determining the expression 
of V317 during the development of M58-66-specific  CTL lines in 21 unrelated HLA-A0201 
subjects, and analyzing TCR usage by M58-66-specific CTL clones. TCR V317 was the dominant 
V3 segment used and CD8 V~17 expansion correlated with M58-66-specific  lysis. Limiting 
dilution analysis from five subjects showed the M58-66 CTL precursor frequency to vary between 
1/54,000 and less than 1/250,000, and that up to 85% of the matrix peptide (M58-66)-specific 
CTL used the V317 gene segment. The M58-66 specific CTL response was dependent on previous 
viral exposure and specific V317 expansion, as it was not found in cord blood, despite a readily 
expandable V317 + CD8 + T cell subpopulation. Sequence analysis of 38 M58-66-specific  V317 
transcripts  from 13  subjects  revealed extensive  conservation in the CDR3  region including 
conservation of an arginine-serine motif. To test the dependence of this CTL response on the 
V[317 gene segment, peripheral blood lymphocytes were depleted of CD8 + TCR V317 + cells, 
before the generation of M58-66-specific  CTL. In most cases such depletion blocked or severely 
reduced the generation of the M58-66-specific  response, and under limiting dilution conditions 
could abolish M58-66-specific CTL precursors. These studies reveal the dependence of this natural 
human immune response on a particular TCR gene segment. 
V 
irus-specific CTL play a role in viral clearance after both 
acute and persistent virus infections in humans (1, 2) 
and experimental infections (3, 4). Viral proteins are processed 
to peptides and translocated via peptide transporters to the 
endoplasmic reticulum where they access class I molecules 
(5-7). The diverse array of peptides, presented by the six poten- 
tial class I molecules, is balanced by the specificity of the T 
cell response encoded within the TCR-ot/3.  While the host 
may benefit from a broad antigen-selected T cell repertoire, 
decreasing the chance that a rapidly mutating organism will 
evade immune detection, TCR diversity will be limited by 
a number of factors, including positive and negative selec- 
tion and interaction with the peptide/MHC complex. 
79 
Both TCR heterogeneity (8) and conservation (9-13)  to 
a specific MHC class I peptide complex has been described. 
Whether immunity after natural infection leads to restric- 
tions on TCR usage remains unclear. Furthermore recurrent 
exposure of an outbred population to a pathogen may elicit 
a different  response  to that seen in experimental systems. 
We have studied the TCR usage of CTL specific for the 
influenza A matrix protein-derived peptide (M58-66),  pre- 
sented by the HLA-A0201  molecule. This immune response 
is of considerable  interest. First,  influenza A is a common 
viral infection of humans and the majority of adults have sero- 
logical evidence of previous influenza A exposure.  Second, 
HLA-A0201 is one of the most frequent class I alleles being 
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A virus-specific CTL response is of special  significance as, 
unlike  other virus-derived peptide epitopes (14),  no other 
HLA-A0201-restricted influenza A-specific epitopes have been 
isolated.  This CTL response was first described using vac- 
cinia virus recombinants  (15) and the optimal matrix pep- 
tide 9 met (M58-66) subsequently defined (16, 17). The HLA- 
A0201/peptide  complex has  since become one of the best 
studied in humans  such that  recent  x-ray crystallographic 
studies have defined the orientation  of each amino  acid in 
the MHC class I binding  deft (18). 
The conservation of TCR usage in a large human popula- 
tion after natural infection has not been determined.  In an 
initial study we described conserved TCKVOt, V~, and Jot 
usage in seven clonally derived lines from two unrelated in- 
dividuals of similar haplotype (12). These preliminary inves- 
tigations raised several questions:  how far  is the restricted 
usage of V~/17 observed in a wider HLA-A0201  population, 
and how is V/317 usage influenced by in vitro culture?  To 
what extent is TCK conservation also retained across the pro- 
posed peptide binding CDK3 region (19), and can non-V/317 
CTL substitute for V/317 in the HLA-AO201/M58-66  CTL 
response? 
We found that (a) long-term CTL clones show conserva- 
tion of both ot and B chain usage.  (b) Using a donotypic 
VB17-specific mAb there is dominant use of the TCR VB17 
segment in both bulk culture lines and CTL clones; limiting 
dilution  culture suggests that  between 55 and 85%  of all 
M58-66-specific CTL clones use this VB chain.  (c) Direct 
TCR sequencing  of limiting  dilution  analysis  (LDA) ~ de- 
rived clones shows a conserved arginine-serine  motif in the 
predicted CDR3 region, and conserved length of the CDR3 
loop for each J~ chain identified. (d) Finally,  V/317 depletion 
of PBMC in some subjects can abrogate the CTL response 
to the M58-66 peptide, suggesting that manipuhtion of human 
class I restricted CTL responses by V/~-specific  mAbs may 
be a possible approach  to immunotherapy. 
Materials  and Methods 
Donors.  Donors were healthy HLA-typed volunteers (n =  23) 
or subjects  with juvenile rheumatoid arthritis (n = 6). No significant 
differences with respect to the HLA-A0201-restricted CTL response 
were observed between the groups. 
Cell Lines.  EBV-transformed lymphoblastoid B cell lines were 
established by conventional methods using supernatant  from the 
EBV-producing marmoset cell line B95.8 (type 1 isolate). CIK.A2 
was a kind gift from Professor A. McMichad (Institute  of Molec- 
ular Medicine, John Radcliffe Hospital, Oxford, UK). CIR.A2 ex- 
presses a transfected genomic done of HLA-A2.1 (20). It was grown 
in RPM11640 with 10% FCS and 400/~g/ml G418 (GIBCO BRL, 
Gaithersburg,  MD). CIR.A2 M57-68 and CIR.A2 M58-66 are 
CIR.A2 ceils transfected with minigene DNA encoding influenza 
virus matrix  peptides B57-68 and M58-66, respectively (17, 21). 
1  Abbreviations used in this paper: CTLp, CTL precursor; LDA, limiting 
dilution analysis; MAM, Mycoplasraa arthritidis derived superantigen. 
They were a kind gift from Dr. H. Zweerink (Merck, Sharpe and 
Dohme, Rahway, NJ). 
Virus.  Influenza  A (AX/31) virus was a kind gift from Dr. D. B. 
Thomas and Dr. J. Skehel (National Institute for Medical Research, 
London, UK). The virus had been grown in the allantoic cavity 
of embryonated chicken eggs. The viral hemagglutination  titre, 
determined by fowl red celt agglutination,  was 1,000 HA U/50/zl. 
Synthetic Pepti~  Peptide M58-66 was synthesized commercially 
(Neosystem Laboratoire, Strasbourg, France). Purity was 92% by 
HPLC analysis. 
Mycoplasma arthritidis-derived superantigen (MAM) was a kind 
gift from Dr. 13. C. Cole (University of Utah College of Medicine, 
Salt Lake City, UT). MAM was isolated from M. arthritidis culture 
supernatants,  as previously described (22). 
HLA  Typing.  HLA typing from all donors was performed by 
the Welsh National Blood Transfusion Service (Rhydlafar, Cardiff, 
UK) using a standard microlymphocyte  toxicity  test. 
Virus- and Peptide-specific CTL  Lines and Clones.  Virus- and 
peptide-specific CTL lines were generated as previously described 
(23). To establish peptide specific  dones, PBMC were infected with 
virus and on day 7 after culture  the cells were centrifuged  on a 
Ficoll-Hypaque density gradient and clones set up in limiting dilu- 
tion culture with replicate input cell numbers at 1, 2, 5, 10, 15, 
20, and 50 cells/well. Replicates for each input cell number ranged 
from 400 (1 cell/well) to 25 (15 cells/well). The cultures were stimu- 
lated  with  peptide-pulsed  irradiated  autologous  B  cells  (1  x 
llY/well), fresh allogeneic PBMC from at least three donors (1  x 
10Vwell), PHA (2/~g/ml)  (Sigma Chemical Co., St. Louis, MO) 
and lymphocult-T (Biotest, Dreieich, Germany); this protocol was 
repeated every 7 d. Fresh medium (RPM11640/10%  human serum) 
and lymphocult-T were added every 3--4 d. Positive wells, as deter- 
mined by phase contrast microscopy, were screened from day 14. 
Only wells that came from plates within the conventional clonal 
distribution  of outgrowth, which by LDA were found to be wells 
with an initial input number of <5 cells/well were expanded. Posi- 
tive wells which fell below this input cell number were screened 
for peptide-specific cytotoxic activity and positive cultures trans- 
ferred into  24-well plates. 
Limiting Dilution Cultures  for Peptide-specific CTL Precursors.  Fresh 
PBMC infected with influenza A virus were inactivated with human 
serum, and added to freshly isohted PBMC to give a final concen- 
tration of 10% infected cells. Replicate microcultures (25-50 repli- 
cates/input cell number) of PBMC and 10% virus infected PBMC 
were set up in 96-well round bottomed plates, with PBMC dilu- 
tions varying from 5,000-150,000 cells/well. After 7 d each well 
was fed with fresh medium, recombinant human IL-2 (10 IU/ml) 
(Boehringer  Mannheim  Corp.,  Indianapolis,  IN)  and  M58-66 
peptide-pulsed B ceils at a feeder to responder ratio of 1:3. Each 
weU was refed on day 14 and given fresh medium and II:2 every 
3-4 d. The LDA was assayed on day 18. Split-well analysis was 
performed  on  two  sets of targets  (untreated  or  M58-66  pep- 
tide-treated CIK.A2 cells). To perform the assay  half the resuspended 
well volume was divided into two aliquots and each aliquot was 
assayed for cytotoxicity on the respective  targets. Maximal and spon- 
taneous release was measured for each plate. Analysis against un- 
treated and peptide-pulsed CIR.A2 cells was performed as described 
(24), using a threshold of 10% specific lysis. Where the single-hit 
Poisson model was fulfilled (a straight line relationship demonstrated 
by the X  2 value for goodness of fit) the regression line was calcu- 
lated by the maximum likelihood method (25). The peptide-specific 
CTLp frequency was estimated  from  the initial  responder  cell 
number at which 37% of the wells were negative for cytotoxicity. 
Statistical analysis was performed using Statistical Package for So- 
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(Royal Statistical Society,  London,  UK). 
The remaining 50% of cells were continued in culture for a fur- 
ther 7-10 d. Those wells which by LDA originated from a single 
HLA-A0201/M58-66-specific CTL precursor, and control wells, 
were subsequently split three ways: (a) to confirm M58-66-specific 
cytotoxicity; (b) for CD8 + TCR Vr  § usage; and (c) total RNA 
was extracted from HLA-A0201.1/M58-66-specific  wellg which 
were shown by dual color immunofluorescence to contain >9.2% 
CD8 +, TCR V/317 + cells (mean  +  3 SD of CD8 +, TCR V317 * 
PBMC). cDNA synthesis and PCR was subsequently performed 
on these samples for sequencing studies (see below). 
Cytotoxicity Assays.  Target cells (EBV-transformed B cells or 
CIR.A2 cells) were pelleted, resuspended in minimal volume, and 
loaded with 51Cr (Amersham International, Little Chalfont, UK) 
(100/xCi of a 10 mCi/ml stock) for 1 h. Virus-infected target cells 
were infected  overnight with  virus, before S~Cr labeling;  while 
peptide-treated targets were pulsed with peptide (final concentra- 
tion 250/xg/ml) for 45 rain after SlCr labeling. The targets were 
then washed and resuspended at 4  x  104/ml in RPMI 1640/FCS- 
10,  and 4  ￿  103 target cells added to 96-well  plates  containing 
50 #1 effector cells in RPMI 1640/FCS-10.  After a 3.5-h incuba- 
tion,  the cells were centrifuged,  15/A  supernatant  spotted onto 
glass-fiber mats (Wallac, Milton-Keynes,  UK), and the radioactivity 
released measured on a 3-plate counter (Wallac).  All assays were 
performed in triplicate.  Target cells incubated with 5%0 Triton X 
(Merck, Poole, UK) or medium alone were used to determine max- 
imal and spontaneous release. Percent  specific lysis was calculated 
from the formula:  100  x  (E  -  M/D-  M),  whereE  =  ex- 
perimental release; M  =  release in the absence ofCTL; D  =  max- 
imal release  following incubation in 5% Triton X.  Spontaneous 
release averaged 9% in all assays and never exceeded 18%. Percent 
net SlCr release  was calculated  as the difference  between percent 
specific S~Cr release  from peptide pulsed and unpulsed targets. 
Flow Cytornetric Analysis and Antibodies.  Flow cytometric anal- 
),sis of cell surface molecules was performed on a FACScan |  440 
flow cytometer (Becton Dickinson & Co., Mountain View, CA). 
Single-color immunofluorescence was performed as described (27). 
For two-color analysis,  cells were incubated with  the first  mAb 
at 4~  for 25 rain, washed three times in PBS-1%  FCS followed 
by goat anti-mouse Ig-FITC for 25 min at 4~  The cells were 
washed three times and incubated with a murine IgG antibody, 
to block available goat anti-mouse Ig-FITC binding sites. The PE- 
labeled second antibody was added and after a 25-min incubation 
the cells were washed a final  three times before fixing in a 2% 
paraformaldehyde solution. 
The following mAb were used:  CD8PE (Becton Dickinson & 
Co.), BMA031 (anti-TCK-oU3) (T Cell Sciences, Lab Impex, Mid- 
dlesex, United Kingdom), C1 (anti-V317)  (28). V317 (anti-V319) 
(Immunotech International, The Binding Site, Birmingham, UK). 
The TCK V gene nomenclature used in this paper is based on Choi 
et al. (29). The commercial Immunotech anti-VB17 antibody uses 
a different nomenclature (30), and by the Choi nomenclature has 
specificity  for VB19. 
Anchored PCR.  Anchored PCR was performed as previously 
described (12). 1-5 #g of total KNA was used from each sample 
and cDNA synthesized using a 5' anchor primer. The PCR prod- 
ucts  were size selected  on  an acrylamide gel and cloned into  a 
modified M13mp18 vector using NotI and SalI restriction sites. After 
transformation of Escherichia coli, plaques containing TCK inserts 
were sequenced using DNA T7 polymerase. 
Sequencing of VjS17 § Clones.  Total  RNA  was isolated  from 
clonally derived cultures (~8  x  10  s cells) using a standard KNA 
extraction  kit  (RNAzol  B;  Biogenesis,  Bournemouth,  United 
Kingdom). cDNA synthesis from mRNA was achieved using a 
poly-T oligonucleotide  primer  (oligo dT).  Oligo-dT12-1s (Phar- 
macia, St. Albans, Hertfordshire, United Kingdom) was annealed 
to 1-5/~g total RNA at 70~  for 5 min and snap chilled  on ice 
for 3 min before addition of reaction buffer.  Reactions were per- 
formed using 2 mM dNTP (Promega, Southampton, UK), 20 mM 
dithiothreitol  (DTT),  10  mM Tris-HC1,  50  mM  KC1,  10  mM 
MgC12, 5 U  human placental RNAase inhibitor (Gibco, Paisley, 
UK) and 100 U murine Moloney leukemia virus reverse transcrip- 
tase (Gibco) at 42~  for I h, before inactivation of routine Moloney 
leukemia virus reverse transcriptase for 5 min at 95~  cDNA (2 
/A/reaction) was then subjected  to PCR using 2.5  U  Taq poly- 
merase (Promega) on a Techne Thermal Cycler in a final concen- 
tration of 2.3 mM MgCl2.  PCR mix was placed on ice immedi- 
ately after adding template, then transferred directly to a hot (95~ 
PCR  block  to  begin  denaturation  for  3  rain  at  95~  Cycle 
parameters were 95~  for 30  s,  55~  for 30 s, and 72~  for 1 
rain for 30 cycles. The VB17 and CB PCR primers used were as 
described  (28). 
The amplification products from four PCR reactions (for each 
clone)  were  then  pooled  and  purified  using  a  standard  PCR 
purification  kit (QIAquick-spin;  Qiagen, Hybaid, Middlesex, UK). 
Purified products were dried and resuspended in 20-40/il distilled 
water for sequencing. Direct cycle sequencing was performed on 
a Techne  Thermal Cycler,  using  the PIklSM  TM  Ready Reaction 
DyeDeoxf  M Terminator  cycle sequencing kit (Applied Biosystems, 
Inc., Foster City, CA), and sequences  read on an automated se- 
quencer (Applied Biosystems,  Inc.). Primers used for sequencing 
were the same as used  during amplification. 
Results 
Conservation of the HLA-AO201.I/M58-66-slaecific  CTL Re- 
sponse.  Using  anchored  PCR  we  studied  the TCR  usage 
of HLA-A0201/M58-66-specific clones and clonally derived 
lines  from a further  two  unrelated  individuals  (Fig.  1).  In 
3/4  cases these clones  used  the  same Vo~ (Vcel0)  and  3/4 
clones used the same V3 (V317). Despite having been gener- 
ated from unrelated individuals in different laboratories, CTL 
clones  were  identifed  which  used  identical  oe and  3  gene 
joining  segments to those previously reported  (12).  In the 
previous and present study, clones from all four individuals 
had been maintained in vitro for more than 2 mo, requiring 
repeated  stimulation  with  virus-infected  or peptide-pulsed 
stimulator  cells. 
Thus as TCR V317 was a frequently used M58-66 specific 
V/3 chain, we used the TCR V317-specific monoclonal anti- 
body C1 to determine the expansion of V317 + CD8 + cells 
in  CTL bulk  culture  cell lines  from  10  to  >100  d  (Tables 
I  and 2). In 11 of the 21 individuals where PBMC were ex- 
amined before secondary in vitro stimulation, no significantly 
expanded  population  of  TCR  V317 +  cells  in  peripheral 
blood was observed. The mean percent  _+ SD V317 CDS/total 
CD8 from freshly isolated PBMC in  HLA-A0201  individ- 
uals was 4.23  +  1.54  (n  =  11),  and  in  age-matched  non- 
HLA-A0201 individuals was 4.17  +  1.18 (n  =  10; not shown). 
After in vitro culture,  all 21  HLA-A0201-positive individ- 
uals were eventually able to generate an M58-66-specific re- 
sponse,  although  poor  responders  required  up  to  two  re- 
stimulations  with  the  peptide.  The  development  of  an 
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ZEll  V~I7  C  A  S  S  T  R  G  A  Y  E  Q  Y  F  J~2.7 
tgtgccagtagtacccggggggcctacgagcagtacttc 
ZEII  VUI0.2  Y  L  C  A  G  A  T  G  N  T  O  K  L  I  F  Jul4.1 
tacctctgtgcaggagctaccggcaacacaggcaaactaatcttt 
]WU]~  V~17  C  A  S  S  I  R  S  S  Y  E  Q  Y  F  J~2.7 
tgtgccagtagtattaggagcagctacgagcagtacttc 
V~I0.2  Y  L  C  A  G  G  G  S  Q  G  N  L  I  F  Ju9.11 
tacctctgtgcaggaggaggaagccaaggaaatctcatcttt 
Donor JM 
JM22  VI117  C  A  S  S  S  R  S  S  Y  E  Q  Y  F  J~2.7 
tgtgccagtagttcga~gagctcctacgagcagtacttc 
Val0  c  A  G  A  G  S  Q  G  N  L  I  F  J(xg.ll 
gtgcaggagcgggaagccaaggaaatctcatctttg 
V~4  C  s  v  L  Q  G  S  P  Y  E  Q  Y  F  J~2.7 
tgc  agcgt  t  t  t  acagggaagcccc  t  acgagcagtac  t  t  c 
VtX2.2  C  A  V  N  S  Y  Y  N  Q  G  G  K  L  I  F  Ju14.2 
tgtgccgtgaacagctattataaccagggaggaaagcttatcttc 
Figure  1.  Nucleotide  and  pre- 
dicted amino acid sequences of the 
TCR c~ and fl chains from anchored 
PCP,-amplified HLA-AO201/M58- 
66-specific  independent clones from 
two unrelated donors, JW and  JM. 
The Jcx nomenclature follows that 
of Moss et al. (52). Each/3  chain 
sequence runs from the conserved 
cysteine  to the first phenylalanine in 
the "F-G-X-T" motif found in the 
J  region  (where  X  is any amino 
acid), and are aligned to that con- 
served region. The conserved  CDR3 
arginine-serine  motif  is highlighted. 
These  sequence data are available 
from EMBL/Genbank/DDBJ under 
accession numbers Z35683-6 and 
Z35690-3. 
M58-66-specific CTL response was invariably associated with 
an  expansion  of the  CD8 +,  TCR  VB17 §  population  in 
CTL lines (15-98%) as compared with freshly isolated PBMC 
(<7.5%)  (Table 1 and Fig. 2), an effect not observed with 
antigen specific CTL lines of different peptide specificities 
derived from the same subjects (Table 1). The CD8 +, TCR 
Vf117 + expansion was particularly  apparent in the "blast" 
population of responding PBMC, (as determined by forward 
angle and side scatter) which contained a higher proportion 
(between  17 and 92%)  of VB17 + CD8 + cells (Table 1). 
To determine whether the VB17 expansion is specific for 
the HLA-AO201/M58-66 complex and is not a reflection of 
prolonged in vitro culture with peptide restimulation, we 
have performed the following investigations: (a) After flow 
cytometric analysis  of 12 CD8 + influenza A  virus-specific 
(non-peptide defined), 7 CD8 +, influenza A-specific, class 
I restricted lines (HLA-B27/N383-91,  HLA-BS/N380-89; 
or HLA-A3/NP265-273-specific)  and 6 CD8 + nonspecific 
lines, only one line showed a VB17+CD8+/CD8 + popula- 
tion in excess  of 5%.  (b)  CTL lines stimulated with en- 
dogenously expressing (M58-66 transfected) CIR.A2 cells also 
showed expansion of the TCR Vf117 + population, with a 
Vf117 + CD8 +/CD8 + population of 28%  and specific CTL 
lysis of 39%  (E/T 3:1, day 18) indicating that expansion is 
not conditional on the presence of synthetic peptide. (c) Com- 
parison of identical CTL lines expanded with either virus- 
infected, or peptide-pulsed, autologous B cells  showed the 
virus-stimulated cells to have a TCR V;317+CDS+/CD8 + 
population of 13.5%  and specific  CTL lysis of 25%  (E/T 
ratio 1:1) (day 18),  as opposed to the CTL expanded with 
peptide-pulsed B cells which showed a VB17 + CD8 +/CD8 + 
population of 25 % and specific CTL lysis of 44 %. The V317 
population is therefore expanded after restimulation with both 
virus- and HLA-A0201-specific viral peptide, though the ex- 
pansion was consistently greater with M58-66 peptide alone. 
(aT) An HLA-AO201/M58-66-specific CTL line (GT, Table 
1) generated in a different laboratory (kindly provided by Dr. 
H.  Zweerink) (31)  also showed a greatly expanded (83%) 
VB17 + CDS+/total CD8 + population (Table 1). (e)Using 
PBMC from subjects who made a good HLA-A0201/M58- 
66-specific CTL response, occasional restimulation would fail 
to generate CTL.  When this occurred no V317 expansion 
was observed. 
Generation of HLA-AO201.1/M58-66-specific CTL Response 
after TCR V~17 PBMC Depletion.  Since V;317 is commonly 
used by HLA-AO201/M58-66-specific CTL it was impor- 
tant to determine whether other TCR V gene segments were 
able to either contribute, or substitute for Vf117 in the HLA- 
A0201/M58-66-specific  response.  The Vf117-specific  mAb 
C1  only  partially  inhibited  cytolytic  activity  of a  TCR 
Vf117 + clone (data not shown). An alternative approach was 
to deplete this subset of cells before in vitro stimulation. We 
were unable to achieve TCR VB17- populations of sufficient 
purity with complement or magnetic bead depletion. There- 
fore TCR VfllT+CD8 + T  cells were depleted from freshly 
prepared PBMC  by flow cytometry  (FACS |  440;  Becton 
Dickinson  &  Co.),  and  then  restimulated  in  vitro  with 
influenza AX/31  virus-infected cells.  This was performed 
on three individuals with a representative experiment shown 
in  Fig.  3.  Depletion  of a  Vf117+CD8 +  population  from 
4.8% to 0.18% (96.4%) was achieved. Parallel control deple- 
tions were performed with a TCR Vf119 specific antibody. 
CTL lysis and flow cytometric analysis were examined after 
15-d culture (Fig. 3). Four CD8 TCR Vfl17-depleted lines 
from the same individual were examined. The control CD8 
TCR Vf119-depleted line showed 61% CTL lysis (E/T ratio 
82  Human CTL Recognition of Influenza A Matrix  Protein Table  1.  Expression of TCR  V~17 + CD8 + Cells in PBMC and Peptide-specific Bulk  Culture CTL Lines of Varying Duration 
Culture  Percent net 
CTL lysis* 
Donors  Duration  (E/T  5:1)  PBMC 
Percent CD8 §  TCR V317 +/total CD8* 
HLA-A2.1/M58-66-specific 
CTL line 
Total population  Blast population 
Non-HLA-A2 flus peptide-specific 
CTL line 
Total population  Blast population 
d 
SP  10  41  -  30  52  -  - 
EC  10  40  -  30  40  3.1  2.2 
KD  10  20  -  15  17  -  - 
JM  12  56  2.6  65  75  -  - 
DDC  21  60  3.6  76  -  -  - 
ND  21  53  -  61  57  -  - 
MD  21  30  -  61  82  -  - 
KP  21  24  3.6  45  69  -  - 
LB  21  28  -  38  49  -  - 
ID  21  49  7.35  47  69  -  - 
JD  21  41  -  32  51  -  - 
MJ  28  23  4.1  13  29  -  - 
PL  28  37  5.3  43  61  5.7  8.26 
GW  36  60  -  65  92  -  - 
AF  36  50  -  25  57  -  - 
MP  42  :>80  6.03  98  -  2.6  3.5 
SW  42  ~'80  3.5  85  -  -  - 
GT  II  ~>28  75  -  83  -  -  - 
JW  ~>100  ~>80  4.1  87  -  0.75  - 
LM  ~  10  -  3.5  -  -  3.5  2.8 
* PBMC and peptide-specific CTL lines were analyzed by two-color  immunofluorescence staining for distribution of TCR. V~17 + staining within 
the CD8 + population. Data are expressed as percent  TCR V/317+ CD8 + cells within the total CD8 + subset. 
CTL lysis is net lysis measured at an E/T ratio  of 5:1. 
S Non-HLA-A0201/M58-66-specific  CTL lines were influenza peptide-specific CTL lines, from the same subject recognizing influenza A-derived 
peptides restricted  through either  HLA-A3, B8, or B27. 
MI CTL line provided by Dr.  H.  Zweerink. 
I CTL line from  non-HLA-A0201 individual. 
10:1) with a 72%  CD8 +V317 + population. After the V317 
depletion, two lines showed no specific lysis and no cell sur- 
face staining for TCR VB17. One line showed 20% lysis (E/T 
10:1) and was found to have an 18.3%  CDS+TCR  V~17 + 
population, which must have been expanded  from  the  re- 
sidual  population  of such  cells  despite  initial 96%  deple- 
tion. The fourth line showed 35%  lysis with no detectable 
CD8 +  TCR  V317 +  lymphocytes,  implying use of a  non- 
VB17TCR.  Further studies on two different subjects found 
no non-V317 HLA-A0201/M58-66-specific CTL response 
in one, and 1/4 non-V317 CTL lines had specific killing in 
the  third  subject.  To more  accurately quantitate the  effect 
of V317 CD8 depletion, this study was repeated under lim- 
iting dilution conditions. Control depletion showed an HLA- 
A0201/M58-66 CTLp of 1/280,000 which became undetect- 
able after  V317  depletion (data  not  shown). 
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While the V317 response appears to be dominant, some 
subjects are able to generate a non-V~17, HLA-AO201/M58- 
66-specific CTL response. The low precursor frequency of 
these non-V317, M58-66-specific CTL (see below) has made 
it difficult to clone out  this population and only one such 
clone has been established to date (Fig.  1).  This clone used 
V34 and Vo~2.2 variable region genes, with no recognizable 
junctional sequence similarity to the V317, VoL10 TCR clones. 
Primary or Secondary Immune Response.  The ubiquitous na- 
ture of the M58-66-specific CTL response in 21 HLA-A0201 
individuals studied,  raised the question whether  this was a 
true  memory response  to  influenza A,  or  if the  naturally 
processed 9-mer peptide could induce a primary CTL response 
in vitro. Cord blood from HLA-A2 phenotyped neonates (as 
detected by mAb MA2.1) and a corresponding maternal sample 
were stimulated for more than 3 wk in vitro with virus- or Table  2.  Comparison of M58-66-specific Lysis and CD8  TCR  Vfll7 Expansion in HLA-A2 Maternal 
and Paired Cord Blood Samples 
Pair  1  Pair  2  Pair 3 
Percent  V/~17  Percent  net  Percent  V~17  Percent  net  Percent  VB17  Percent  net 
CDS/total CD8  CTL lysis*  CDS/total CD8  CTL lysis  CD8/total CD8  CTL lysis 
Cord 
Day 1  3.9  4  3.2 
Day 18  7  0  7  0  8  0 
Mother 
Day 1  4.5  1.9 
non-HLA-A2 
Day 18  18  37  27  34 
* Percent net CTL lysis was calculated as the difference between percent specific SlCr release from peptide-pulsed and unpulsed targets. 
peptide-infected  cells.  No  HLA-A0201  M58-66  peptide- 
specific killing or TCR V/317-expanded cells in 3/3 cord blood 
samples was found, whilst 2/2 matching (HLA-A2) maternal 
samples showed peptide-specific lysis and expansion of the 
CD8 +  VB17 + cells  (Table  2).  The  lack  of cord blood re- 
sponse was not a result of an inability to expand the VB17 
repertoire  as  MAM-treated cord blood samples  rapidly ex- 
panded TCR V/~17 expressing cells from 4-26% of the total 
population after 7 d in culture. Despite MAM-induced CD8 
and CD4 TCR V/317 expansion in cord blood there was no  8o 
peptide  specific killing.  However,  it  should be noted  that 
MAM-induced V/317 expansion from adult donors also does 
the proportion of CD8+V/~17 § lymphocytes in CTL in the 
HLA-A0201/M58-66 specific CTL response, we used LDA 
to determine the M58-66-specific CTLp frequency and then 
analyzed the V/~17 CD8 cells of all microcuhures from plates 
with input  cell numbers indicative  of single precursor cell 
origin. Only HLA-A0201/M58-66-specific wells with input 
cell number  <150,000 were analyzed. 
Depletion  V~17CDS/ 
total CD8 
vp19-  72% 
not result in specific expansion of an M58-66-specific CTL  ~  so 
.I 
population  (P. J.  Lehner,  unpublished  observations).  >. 
Quantitation of the CD8 + TCR  Vf117 + Proportion of the  ~ 
HLA-AO201/M58-66-specific CTL Response.  To quantitate  ~  4o  . 
v~17-  <1% 
loo  _  loo  ~  j,D 
t  ~  20  vpl  7.  18.3% 
I 
80  80  ,,  vpl 7.  < 1% 
.-  ,  vp17.  <1% 
0  60  o  ~..  0  ................... 
,41- ~176176  I-  /,---..---  .. 
40  4  /,;  .'""  40  .~  E T ratio 
..  ￿9  .  Figure  3.  TCR V/317  +  CD8 + depletion reduces M58-66 peptide- 
I]  /  "'"~:P~  "r  "i''  "  20  t~  specific  CTL generation but  allows detection of V~17-CTL.  TCR  20 
1~  #  V317§  + and control (TCR V/319+CD8  +) T cells were depleted 
0  ,-  0  from PBMC population by cell sorting. Remaining cells were stimulated 
with influenza A virus and plated in 96-well fiat-bottomed plates at 1 x 
106/well, to  ensure HLA-A0201/M58-66 CTLp  were present in  the 
microcuhure (Table 3). A 96% V~17+CD8 + depletion of a-4.8% V~17  + 
CD8 + staining population was achieved. Net CTL lysis and the propor- 
tion of V/317  § CD8 § cells were estimated after 15-d culture. Eight lines 
were examined. Four TCR VB19-depleted CTL lines (-B-) all recog- 
nized M58-66. One of four TCR V~817-depleted lines (-C]-) recognized 
M58-66 and was TCR V~17-ve. One line (-0-) showed 10% lysis but 
was found to have an 18.3% VB17  + CD8 + population, despite the ini- 
tial 96% depletion. The remaining two V/~17-depleted lines (-/~ --A-) 
showed <10% lysis, and contained <1% VB17  + CD8 + cells. 
0  10  20  30  40  50 
Culture duration (days) 
Figure  2.  VB17  + CD8 * CTL expand after secondary  in vitro stimu- 
lation and continued culture. The proportion of V/~17 + CD8 + T cells 
(  ), and peptide-specific cytotoxicity (  .... ) of high (-C-, - -O- -), 
medium (--{2-, - -I- -) and poor (-A-, - -&- -) responder bulk culture 
lines was measured after fresh PBMC were cultured in vitro with influenza 
A-infected cells and pulsed at weekly intervals with M58-66 peptide and 
feeder cells. The effector/target ratio was fixed at 5:1. 
84  Human CTL Recognition of Influenza A Matrix Protein Table  3.  Quantitative  Analysis of the CD8 + TCR  V~17 + Contribution to the HLA-A2.1/M58-66-specific CTL Response 
Frequency of HLA-A0201/ 
M58-66-specific CTLp in PBMC* 
HLA-A0201/M58-66-specific 
CTL clonal cultures 
Non-HLA-A0201/M58-66-specific 
CTL clonal cultures 
CD8 + V/~17 +  Non-V317  CD8 + V317 +  Non-V317 
wells*  wells  wells  weUs 
%  %  %  % 
DDC  1/54,000  5/9 (55.5)  4/9  (44.5)  0/4 (0)  4/4 (100) 
SW  1/105,000  24/35  (68.5)  11/35  (31.4)  0/3  (0)  4/4 (100) 
AF  1/170,000  14/20  (70)  7/20 (30)  2/38  (5.3)  36/38  (94.7) 
PL  <1/250,000  9/12 (75)  3/12 (25)  0/2 (0)  2/2 (100) 
JWS  1/215,000  23/32  (71.8)  9/32 (28.2)  1/22 (4.5)  21/22  (95.5) 
JW  (1)  1/275,000  (approximately)  7/9  (77.7)  2/9 (22.2)  0/4 (0)  4/4 (100) 
JW  (2)  -  8/9  (88.8)  1/9 (11.2)  3/34 (8.8)  31/34 (91.2) 
* LDA were established  and assayed  for M58-66-specific  CTL activity  as described  in Materials and Methods. ClonaUy  derived  HLA-A0201/M58-66-specific 
CTL and M58-66-negative controls were expanded in culture and the proportion of CD8* TCR VB17  + cells in the microcultures determined. 
* A positive CD8 + TCR Vf117+ well was defined as a well with a CDS+ TCR. Vf117+ population >9.2% (mean _+  3 SD) of the total CD8 + 
population. 
S Individual JW was tested for the CD8 + TCR V317 + contribution on three separate occasions over a 6-mo period. 
It is di~cult to ascertain a cut-off for V317 positivity. The 
mean percent  +  3 SD VB17 CD8/total  CD8 from freshly 
isolated PBMC in 25 subjects was 9.2%. While the percent 
V317 CD8/total CD8 in LDA cultures ranged from <1 to 
98%,  102/108  (94.4%)  M58-66-negative  cultures  showed 
a VB17 CD8/total CD8 <10%. Therefore in the LDA anal- 
100 
r 
initial responder cell number x 10"3 
0  100  200  300 
' 
Figure 4.  Estimation of frequency of total, and TCR V317 + CTL 
precursors against the HLA-A0201/M58-66  complex. Fresh PBMC (from 
AF) were cocultured with 10% influenza-infected  autologous PBMC and 
restimulated on day 7 with hlL-2 and peptide-pulsed B cells. On day 18 
the cultures were assayed  for cytotoxicity against uninfected and peptide- 
pulsed CIR..A2 cells as described. M58-66-specific  wells indicative  of single 
precursor cell origin were allowed to expand in culture for a further 5 d, 
and reexamined  for cytotoxicity and CDS, Vf117  dual staining. The CTL 
precursor frequency  is estimated from the intercept of the regression  line 
at 37% negative wells. M58-66-specific  CTLp (1/170,000 PBMC, upper 
and lower 95% confidence intervals, calculated by the method of max- 
imum likelihood: 1/236,673 and 1/130,197, X  2 =  0.156), TCR Vf117  § 
M58-66-specific  CTLp (1/280,000 PBMC, upper and lower 95% confidence 
intervals: 1/194,000 and 1/410,000, X  2 =  0.5). 
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ysis a well was considered to be V~17 positive if >10% V~17 
CD8  cells were present. 
Five individuals were studied (Table 3, Fig. 4). Microcul- 
tures originating from a single CTLp, in which the CD8 + 
V~17 § population exceeded 10% of the total CD8 popula- 
tion were observed in 55.5-89% of microcultures with M58- 
66-specific cytotoxicity. In contrast, only 6/108 (5.6%) M58- 
66 CTL negative wells had >10% CD8+V317 + usage. Re- 
peat analyses were performed on three separate occasions in 
the same subject (JW) over a 6-mo period. The CD8 V~17 
CTL varied between 72 and 89% of the total HLA-A0201/ 
M58-66-specific CTL response. 
Direct Sequencing of LDA-derived  V~17 + Clones.  LDA 
studies confirmed the dominance of VB17 + CD8 + CTL in 
the HLA-A0201-restricted M58-66 peptide-specific response. 
However  a  question  remained  as  to  whether  the  TCR 
V317 + chains showed restriction in their CDR3 region, en- 
coded within the junctional (V-D-J) region of the B chain. 
We used the mAb C1 to identify which wells among all CTL 
recognizing this peptide were VB17 + and these wells were 
allowed to expand by further in vitro culture.  Using  only 
those cultures  originating from input  cell numbers which 
indicated that the culture was clonal, V317-specific primers 
were used to amplify, done, and sequence the dominant V317 
sequence in  these wells.  Although  "non-M58-66-specific" 
polyclonal V317 TCR-3 chains will also be present in these 
wells,  any dominant  clonal population is preferentially ex- 
panded by primer  selection for direct sequencing.  Reverse 
transcriptase-PCR  was  performed on 43  M58-66-specific, 
V317-positive microcultures from 11 individuals. Sequences 
were  obtained  from  30  of these  LDA-derived  clones  and 
shown,  together  with  the  anchored  PCR-derived  V317- 
positive transcripts, in Fig.  5. The results show that 26/38 J~2.7 
JWZEII*  C  A  S  S 
Cgtgccagtagt 
MPB6*  C  A  S  S 
tgtgccagtagt 
JM22"  C  A  S  S 
tgtgccagtagt 
JAVUB8"  C  A  S  S 
tgtgccagtagt 
MODG5  c  A  s  s 
tgtgccagtagt 
HLEI8  c  A  S  S 
tgtgccagtagt 
DDD4  C  A  S  S 
tgtgccagtagt 
DDD8  c  A  S  S 
tgtgccagtagt 
DDEI  c  A  S  S 
tgtgccagtagt 
NMH8  c  A  s  s 
tgtgccagtagt 
MODG4  c  A  S  s 
tgtgccagtagt 
KE~9  C  A  S  S 
tgtgccagtagt 
DDE5  c  A  S  S 
tgtgccagt~gt 
BDE8  c  A  S  S 
tgtgccagtagt 
JNJI  C  A  S  S 
tgtgccagtagt 
SWAI3  C  A  S  S 
tgtgccagtagt 
SWAI0  C  A  S  S 
tctgccagttcg 
TRGAYEQYF 
acccggggggcctacgagcagtacttc 
SRSAYEQYF 
agca~ntc~gcctacgagcagtacttc 
SRSSYEQYF 
tcgaggagotcctacgagcagtacttc 
IRSSYEQYF 
attaggaffcagctacgagcagtacttc 
IRSSYEQYF 
atcegcagctcctacgaacagtacttc 
IRSSYEQYF 
atcagga~etcgtacgagcagtacttc 
IRSSYEQYF 
atc~gnaffetcctacgagcagtacttc 
IRSSYEQYF 
att~gnaG~tcctacgagcagtacttc 
IRSSYEQYF 
atc~tcgtacgagcagtacttc 
IRSSYEQYF 
ataaggtccagctacgagcagtacttc 
MRSSYEQYF 
atga~tcatcctacgagcagtacttc 
IRSAYEQYF 
atca~a~gcctacgagcagtacttc 
MRSSYEQYF 
atg~ffat~gagctacgagcagtacts 
IRSADEQYF 
ata~g~ccgcc~acgagcagtacttt 
MRSSYEQYF 
atgag~g~tcctacgagcagtacttc 
MRSGPEQYF 
atgag~tccgggcccgaacagtacttc 
SRAAVEQYF 
tctcgggcagcggtc~aucautacttc 
J~z.3 
MPB3*  c  A  S  S 
tgtgccagtagt 
MPB7* C  A  S  S 
tgtgccagtagt 
MPBS*  C  A  S  s 
tgtgccagt  agt 
SWA20 C  A  S  S 
tgtgccagtagt 
KDA24 C  A  S  S 
tgtgccagtagt 
HIll9  c  A  S  S 
tgtgccagtagt 
HL~3  C  A  s  S 
tgt~ccagtagt 
JN5K2  c  A  S  s 
tgtgccagtagt 
NMHI2c  A  S  S 
tgtgccagtagt 
J~2.2 
MPBS*  C  A  S  S 
tgtgccagtagt 
KEFII  C  A  S  S 
tgtgccagtagt 
J,z.l 
CLH3  c  A  s  s 
tgtgccagtagt 
JNBJI2  C  A  S  S 
tgtgccagtagt 
PRSTDTQYF 
cctag~ag~acagatacgcagtatttt 
TRSTDTQYF 
acaag~agcacagatacgcagtacttc 
SRSTDTQYF 
agtcg~ag~acagatacgcagtatttt 
IRSSDTQYF 
atc~ggagttcagatacgcagtatttt 
MRSTDTQYF 
atgag~agcacagatacacagtatttt 
TRSTDTQYF 
acc~gaag~acagatacgcagtatttt 
GRSTDTQYF 
ggccggagtacagatacgcagtatttt 
MRSTDTQYF 
atgagnmgcacagatacgcagtacttt 
IHGADTQYF 
attcatggtgcagatacgcagtatttt 
I  R  ~  S  G  E  L  F  F 
a  t  aagaagcagcggggagct  g  t  t  t  t  t  t 
I  R  8  D  G  E  L  F  F 
atacflgaflGgacggggagct gt  t  t  t  t  t 
I  R  W  N  G  E  Q  F  F 
atacgtagtaatggtgagcagtttttc 
V  S  S  Y  N  E  Q  F  F 
gtcagctcctacaatgagcagttcttc 
Jl~l.5 
BDE20  c  A  s  s 
tgtgccagtagt 
JECI7  C  A  S  s 
tgtgccagtagt 
J]~l.l 
MODG2  C  A  S  S 
tgtgccagtagt 
M  R  8  S  E  Q  H  F 
atgcflgagctccgagcagcacttt 
Y  Y  R  N  Q  P  Q  H  F 
tat  tatagaaatcagccccagcat  t  t  t 
T  R  S  N  T  E  A  F  F 
acccgatcgaacact  gaagct  t  tct  t  t 
Jill.2 
SWA3  c  A  S  S 
tgtgccagtagt 
SWA9  C  A  S  S 
tgtgccagtagt 
SWAI8  C  A  S  S 
tgtgccagtagt 
MODG9  c  A  S  S 
tgtgccagtagt 
KDAI  C  A  S  S 
tgtgccagtagt 
I  G  }I  Y  G  Y  T  F 
aUcgggaactatggctacaccttc 
Q  G  S  Y  G  Y  T  F 
caggggagctatggctacaccttc 
T  G  S  Y  G  Y  T  F 
acaggatcctatggctacaccttc 
T  G  S  Y  G  Y  T  F 
acgggcagctatggctacaccttc 
I  G  N  Y  G  Y  T  F 
atcgggaactatggctacaccttc 
V~I7  non-killers 
BDEI i  c  A  S  S 
tgtgccagtagt 
DPBK9  C  A  S  S 
tgtgccagtagt 
CLH7  c  A  S  S 
tgtgccagtagt 
N~9  c  A  S  S 
tgtgccagtagt 
IVGTEAFF 
atagtcgggacagaagctttcttt 
VALATEAFF 
gtggccttggccactgaagctttcttt 
SGSETQYF 
agcgggagtgagacccagtacttc 
MGGSYEQYF 
atgggaggctcgtacgagcagtacttt 
Figure  5.  Nucleotide  and predicted amino acid sequences of the VB17/~ chains from anchored PCR-amplified independent (marked by asterisk), 
and V/~17-amplified LDA-derived HLA-A0201/M58-66-specific  CTL clones from 13 donors (see Materials and Methods for further details). Clones 
are listed by J/~ usage, each sequence runs from the conserved cysteine in the VB17 region to the first phenylalanine in the "F-G-X-T" motif found 
in the J region (where X  is any amino acid), and are aligned to that conserved region. The conserved CDR3 arginine-serine motif is highlighted. 
Direct sequences obtained from non-matrix peptide-specific, VB17-expanded wells are shown for comparison. These sequence data are available from 
EMBL/GenBank/DDBJ  under accession numbers Z35670-Z35715. 
(68%) of the TCR V/~17 clones use either theJB2.7 or J/32.3 
gene.  Five different J/3 genes were less commonly used.  Of 
particular interest was the conserved "arginine-serine motif" 
found in the CDR3  region in clones from all 13 individuals, 
and this motif was found in 28/38 (74%) of all the sequenced 
clones.  Seven clones  from  five subjects  used identical junc- 
tional amino acid sequences, all of which differed at the nucleo- 
tide level, providing evidence for selection of this rearrange- 
ment.  The junctional  region  was of constant  length  in  all 
J~2.3  and  2.7  clones,  but  was  a  single  amino  acid  shorter 
in clones using the J~81.2 gene segment.  None of these clones 
showed  the  arginine-serine  motif. 
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The major aims of this study were: (a) to determine the 
degree of TCR o~ and B chain conservation in the human 
CTL  response  to  the  influenza  A-specific  HLA-A0201/ 
M58-66 complex, in a wide range of HLA-A0201 individ- 
uals; (b) to quantitate and sequence the dominant B chain 
used in the CTL response to this naturally occurring human 
virus; and (c) to determine the extent to which the HLA- 
A0201/M58-66 CTL response is dependent on V/317 and ad- 
jacent D-J segments. 
VB17 is the dominant V/~ segment in the CTL response 
to the HLA-A0201/M58-66  complex,  as demonstrated by 
anchored PCR on isolated CTL clones, and the V/317 expan- 
sion of M58-66-specific bulk culture CTL lines. M58-66- 
specific TCR sequences from two unrelated individuals, of 
similar haplotype, have  previously shown conservation of V/~ 
(V/517 8/9 sequences), Vo~ (Voll0 8/12), and Jc~ gene usage. 
In the present study, sequences  of established  long-term clones 
from two further individuals had direct chain pairing of  VB17 
and Voll0, Jo~ conservation  and independent use of V~17 
and  Voll0.  The lack  of available Vczl0  TCR  mAb  has 
precluded further studies of Vo~ usage in bulk culture CTL 
lines. However, VB17 gene usage was not identified in any 
of five HLA-A2 restricted, influenza A-specific CTL clones 
from an individual studied by de Waal Malefyt et al. (32). 
Vo110.2 was used by two of these clones, for which no corre- 
sponding ~ chain was identified. In view of the predominant 
use ofV/517 in the present study, this discrepancy may reflect 
the different matrix peptides used (M59-68 vs. M58-66), or 
the unusual phenotype (HLA-2.1, HLA-2.2F) of their CTL 
donor (Q66)  (33, 34). 
TCR gene usage in human class I-restricted CTL (12, 13) 
has been examined in only a few studies, with small numbers 
of subjects. Conclusions based on a limited number of long- 
term clones from a few individuals may be neither represen- 
tative of short-term bulk culture CTL lines, nor of the in 
vivo situation.  We have therefore examined the kinetics of 
in vitro expansion of the M58-66-specific CTL response from 
initiation  to 3 mo. All individuals generating an M58-66- 
specific response expanded the V/317 § T cells, especially in 
the CD8 + blast population. These cells were detectable early 
and in higher numbers in those individuals with a strong 
M58-66 CTL response. This was not dependent on the pres- 
ence of synthetic peptide as it was also observed after stimu- 
lation with virus-infected cells or CIR-A2 cells expressing 
the minigene encoding M58-66. The VB17 expansion was 
consistently less with virus-infected cells, as the HLA-A0201/ 
M58-66-specific CTL response may be competing with other 
class I restricted viral peptides presented at the cell surface. 
CTL lines restricted through HLA-A0201 but with different 
peptide specificities  have not shown a V~17 preference,  making 
it unlikely that the class I-restricting element alone is respon- 
sible for the V/~17 preponderance  (12). 
We have used LDA to both quantitate the proportion of 
TCP,. V/~17 in the M58-66-specific  CTL response and generate 
M58-66-specific CTL clones for PCR amplification and se- 
quencing.  Analysis of five individuals showed V/~17 to ac- 
count for between 55.5 and 89%  of the TCP, usage in the 
HLA-A0201/M58-66-specific CTL response. This remained 
relatively constant in a single individual tested on three sepa- 
rate occasions over a 6-mo period. This adaptation of LDA 
complements information gained from the generation of  long- 
term CTL clones, by allowing the quantitation of peptide- 
specific TCR usage under culture conditions  which allow 
clonal expansion of M58-66-specific CTL precursors. This 
technique allows the generation of a large number of CTL 
clones for sequence analysis, and comparison of sequences ob- 
tained from established long-term and LDA-derived clones 
shows the data to be consistent. 
The discrepancy between the 90% V/~17 usage in long- 
lived bulk culture lines and the 15-45% "non-VB17" M58- 
66-specific clones suggests  a selective maturation of high 
affinity TCR clones after bulk culture stimulation,  which 
will be precluded under limiting dilution conditions. Whether 
CTL TCtL selection and maturation occurs in vivo is impor- 
tant to determine. Murine studies on the CTL response to 
the H-2Kd-restricted HLA-CW3 170-179 antigen has shown 
a marked TCR preference for VB10 and a unique Jc~ seg- 
ment in 23 independent in vitro derived CTL clones (35). 
This in vitro TCR restriction was paralleled by an in vivo 
study which showed marked expansion of V~10 in PBMC, 
spleen, and draining lymph nodes of mice immunized with 
this antigen, and direct sequencing confirmed similar J and 
junctional chain  usage  in  these  conserved VB10  +  clones 
(36). It is not known whether the TCR expansion after im- 
munization with  an  immunodominant synthetic peptide 
reflects TCR. expansion after natural infection. Future studies 
in humans will need to examine both peripheral blood and 
respiratory tract lymphocytes for TCR V/~17 expansion after 
acute influenza infection. 
The TCR recognition of influenza matrix peptide exhibits 
the most conserved V region segment usage of any studied 
class I-restricted human immune response, and given the re- 
quirement for the V~17 gene segment, several  features of the 
CDR3 region conservation are of note. There appears to be 
relatively little conservation of the JB segment, and although 
J/52.3 and J/~2.7 were used in 65%  of all transcripts,  these 
gene segments are amongst the most commonly used in the 
TCR-fl repertoire  (37). 
More dramatic is the conservation of amino acids in the 
CDR3 region, with the most conserved residue (arginine at 
position 97) used  in 30 of the 40 transcripts (for residue  nomen- 
clature see Chothia et al. [38]). 5 of the 10 transcripts without 
an arginine at this position use a J/31.2 gene segment. There 
are several  examples of conservation of this residue in peptide- 
specific responses  and  in  the  study  of  TCR  usage  in 
H-2Ka-restricted CTL recognizing an HLA-CW3-derived 
peptide, a glycine was found at this position in all TCR-/3 
sequences (35). In the absence of a three-dimensional struc- 
ture of the ternary complex it is impossible to determine where 
the conserved arginine may contact the MHC/peptide com- 
plex. Around this arginine other amino acids show strong 
conservation. A serine is found at position 98 and to a lesser 
87  Lehner et al. extent at position 99 in the majority of transcripts.  Isoleu- 
cine or methionine is usually located at position 96. In con- 
trast to the TCR-o~ sequences used in this immune response 
the length of the B chain CDR3 region is virtually always 
conserved at 11 amino acids between the conserved cysteine 
and phenylalanine residues of V and J segments, respectively. 
The only exceptions are the five transcripts using the J~1.2 
segment and the sequence BDE20. While several features of 
the pattern of amino acid conservation have been reported 
in other murine and human T cell responses there is no similar 
example of such striking TCR conservation  in a natural human 
immune response to a common pathogen. 
The analysis of many different TCR sequences gives in- 
sight into the degree of amino acid diversity that is accept- 
able at each position in the CDR3 loop and acts as a physio- 
logical correlate of murine transgenic analysis (39). As the 
structure of the HLA-AO201/M58-66 peptide complex has 
been solved at the three-dimensional  levels these TCR se- 
quences should eventually assist in the interpretation  of the 
TCR contacts with the MHC:peptide once the crystal struc- 
ture of the TCR is solved. 
Examples of restricted Vfl gene usage with more hetero- 
geneous Vc~ usage have also been found with human class 
II restricted tetanus toxoid-specific T cell clones (40). These 
clones were unusual in that the tetanus toxoid-derived pep- 
tide was promiscuous, being recognized in association with 
several HLA-DR molecules, as has also been reported for other 
class II restricted clones (41, 42). In the report by Boitel et 
al. a particular VB gene product was selected irrespective of 
whether the peptide was presented by four different HLA- 
DR alleles, implying shared MHC molecules were not re- 
quired for shared Vfl gene usage by TCRs specific for the 
peptide. The M58-66 HLA-A0201 restricted peptide is not 
known to bind any other human MHC molecule and although 
class I peptide promiscuity has also been found with both 
human and murine HIV-specific CTL clones (43, 44), in nei- 
ther study was the TCR usage reported. 
The presence of an M58-66-specific CTL response in all 
HLA-A0201-positive adults raised the question as to whether 
the in vitro response was a memory response, or whether 
stimulation  of CD8 cells with the optimal 9-mer peptide is 
capable of activating a primary CTL response in vitro. The 
absence of an M58-66-specific CTL response in cord blood, 
despite a readily expandable Vfll7 population of  lymphocytes, 
and the inability of  either MAM or TCR VB17 mAb-activated 
adult or cord PBMC to generate M58-66-specific killing sup- 
ports the view that the M58-66 response represents a memory 
response acquired by primed individuals in an antigen specific 
manner. The generation of antigen-specific  CTL requires both 
in vivo exposure to virus, and the expansion of specific  junc- 
tional and J/3 receptors to generate CTLp,  a process which 
cannot be mimicked by polyclonal stimulation  of the domi- 
nant TCR V/3 population. The absence of influenza viral per- 
sistence (45), and the lack of reported clinical influenza cases 
in our geographical area during this study, suggests that the 
population is either continually exposed to subclinical infec- 
tion or that CTL memory  is retained for considerable periods 
in the absence of persistent  viral antigen. 
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To  test  the requirement of TCR  VB17 for  the M58- 
66-specific  CTL response, TCR Vfll7 was deleted  from freshly 
isolated PBMC before in vitro expansion. In 10/12 depleted 
CTL lines from three individuals the CTL response was com- 
pletely abolished, and under limiting dilution conditions  a 
low CTLp frequency became undetectable after V317 deple- 
tion. However, analysis of M58-66-positive limiting dilution 
cultures suggested that between 10 and 40% of the response 
may be contributed by VB17-negative  CTL. This discrepancy 
could result from a lack of sensitivity in the culture assay, 
difficulties with the depletion assay or differences in donors. 
While TCR V~17 is clearly the predominant VB gene seg- 
ment in the human M58-66-specific CTL response, other 
non-V~17  gene segments can contribute to this response, 
though only a single V~17 negative clone has been estab- 
lished. These results suggest that while TCR-directed gene 
therapy is a possibility, the role of subdominant TCR requires 
further investigation, in particular whether these clones as- 
sume greater importance after depletion of the dominant CTL. 
Influenza A is a natural, repeatedly encountered infection 
(46). Conserved TCR usage may therefore  reflect  in vivo matu- 
ration and selection for optimal high affinity CTL clones. 
However such marked restrictions  on TCR usage has not 
been found for other flu CTL epitopes (13), and other factors 
also have to be considered. Based on an analysis of reported 
studies of TCR conservation against several class I and class 
II peptides, Casanova and Maryanski (47) have suggested that 
the current conflicting results on TCR conservation  may reflect 
restrictions on TCR usage which would occur when strong 
homology exists between a presented endogenous self and 
foreign peptide. In these cases tolerance to self-proteins may 
trim the range of potential TCRs used in the CTL response. 
However a single amino acid change in a peptide has been 
shown to convert a homogenous TCR response into a heter- 
ogeneous one and the type of TCR response may therefore 
be a function of the peptide itself (48). These observations 
are not exclusive; the restricted TCR usage seen in the human 
M58-66 CTL response  is not as evident in the M58-66-specific 
CTL response in the HLA-A0201 transgenic mouse (49), sug- 
gesting that endogenous factors may influence TCR selection. 
To evaluate  whether the TCR restriction found in the M58- 
66-specific response reflects the requirement to differentiate 
M58-66 from an endogenous homologue, a Swissprot data- 
base search was performed to look for endogenous proteins 
with sequence homology to the matrix peptide and identified 
the endogenous sequence GLLGFVGTL. This 9 mer resides 
within the RING 11 encoded human transporter protein (TAP 
2) (50), at position 57-65, and shares 7/9 residues with M58- 
66, with changes at position 2 and 7 of the peptide.  The 
conservative change from isoleucine to leucine at position 2 
favors HLA-A0201  binding and does not affect CTL lysis 
(51). We have shown that the synthetic transporter peptide 
binds HLA-A0201, but is not recognized by matrix peptide 
specific human CTL clones (P. J.  Lehner, E. C.  Y. Wang, 
S. Williams, and L. K. Borysiewicz, manuscript in prepara- 
tion).  Whether this transporter-derived  peptide is actually 
presented on HLA-A0201-expressing cells remains to be de- 
termined, as processing restrictions may prevent the peptide 
Influenza A Matrix Protein accessing HLA-A0201. This peptide is, however, a potential 
candidate restricting a diverse T  ceU response  to the HLA- 
A0201/M58-66  complex. 
In summary, the CTL response to the naturally occurring 
HLA-A0201-restricted influenza-derived peptide shows con- 
servation of both TCIL-ot  and/3 chain usage.  TCR V~317 
accounts for between 55 and 85%  of all/3 chains used in 
this response,  and is associated with a conserved junctional 
region in the majority of subjects examined. PBMC deletion 
of the  TCR  V/317 gene  segment  can  abolish  the  M58- 
66-specific CTL response. Thus under these conditions there 
is an overwhelming requirement for TCR V/317 to establish 
HLA-A0201/M58-66-specific CTL. 
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